Elanix Biotechnologies Signs Agreement with Dermacon to Develop Progenitor Cell Medical Devices to Accelerate Wound Healing

DGAP-News: Elanix Biotechnologies AG / Key word(s): Agreement/Alliance

01.12.2017 / 08:00

The issuer is solely responsible for the content of this announcement.


 

PRESS RELEASE

Elanix Biotechnologies Signs Agreement with Dermacon to Develop Progenitor Cell Medical Devices to Accelerate Wound Healing

– Accelerates First Cover product commercialization

– Expedites entry into reimbursable market segments

– Creates opportunities in acute and chronic wound care

Nyon, Switzerland and Berlin, Germany, December 1, 2017Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today the signing of an agreement with Dermacon GmbH to develop medical devices for its First Cover wound care franchise. These new First Cover medical devices will incorporate Elanix’s proprietary progenitor cell technology and will be evaluated to significantly accelerate healing in acute and chronic wounds.

Under the terms of the agreement, Dermacon will apply its extensive expertise to design progenitor cell matrix-based products for Elanix and guide the development and CE mark regulatory process. Elanix will retain all commercial rights to any resulting products utilizing its progenitor cells.

“Developing medical devices based on our progenitor cell technology is the next step in our business strategy as the regulatory pathway and reimbursement for cell based products is already very well defined. Our objective is to have one or more products to address the significant need in acute or chronic wound care, gain CE Mark and be launched on the European market by 2020,” commented Tomas Svoboda, CEO of Elanix. “Having developed and launched its own CE Marked dermatological products, we believe that Dermacon is ideally placed to help us meet our objectives.”

The wound management products to be developed under the agreement will incorporate progenitor cells or their derivatives into a product classified as a medical device. These devices enable the controlled release of the cells and their active functional proteins (growth factors and cytokines) to create a healing environment that supports tissue regeneration and helps prevent infections.

Dermacon GmbH is an experienced and competent expert in the production and marketing of high-quality and user-friendly medical devices. The core competence of the company lies in the field of wound care. The range of services also includes the accompaniment and support of scientific studies as well as approvals for medical devices.

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix has its registered office in Berlin, Germany, with an office in Wiesbaden, Germany, and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com.

Press Contacts:

Elanix Biotechnologies AG Halsin Partners
Tomas Svoboda, CEO Mike Sinclair
Tel: +41 22 363 66 40 Tel: +44 (0)20 7318 2955
investor.relations@elanix-bt.com msinclair@halsin.com

 

Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


01.12.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
Kurfürstendamm 32
10719 Berlin
Germany
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

 
End of News DGAP News Service

show this